CClinicalTrials.gg
CompletedNCT07192406Updated Jan 27, 2026

Cross-cultural Adaptation of the Toxic Masculinity Scale Among Indonesian Nursing Students: A Psychometric Testing

An observational study in Masculinity, Nursing and Scale Reliability Validity, sponsored by Kaohsiung Medical University. Completed at 1 site in Indonesia. Open to participants aged 17 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Kaohsiung Medical University · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
672
Ages
17 Years and older
Sex
All
01

Study summary

This study aimed to adapt and validate the Toxic Masculinity Scale (TMS) for use among nursing students in Indonesia, ensuring its cultural relevance and psychometric soundness. The process involved cross-cultural adaptation through translation, expert review, and pilot testing, followed by psychometric evaluation using a sample of Indonesian nursing students.

Read the detailed description

This study aimed to adapt and validate the Toxic Masculinity Scale (TMS) for use among nursing students in Indonesia, ensuring its cultural relevance and psychometric soundness. The process involved cross-cultural adaptation through translation, expert review, and pilot testing, followed by psychometric evaluation using a sample of Indonesian nursing students.

Key steps included: Translation and back-translation of the original scale, Content validation by experts in gender studies and nursing education, Exploratory and confirmatory factor analyses (EFA \& CFA) to test construct validity and Reliability testing using Cronbach's alpha for internal consistency

02

Conditions studied

  • Masculinity
  • Nursing
  • Scale Reliability Validity
  • Student

Keywords

  • nursing
  • masculinity
  • student
  • psychometry
  • scale
03

In context

Lead sponsor

Kaohsiung Medical University is the lead sponsor of 55 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

all nursing students are in indonesia national wide

Inclusion criteria

  • nursing student
  • more than 17 years
  • fluent in the Indonesian language

Exclusion criteria

Exclusion Criteria:

  • catastropic condition
  • gap year during study
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
672 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Toxic Masculinity

    The Toxic Masculinity Scale (TMS-28) measures endorsement of harmful masculine norms across four domains: Masculine Superiority, Gender Rigidity, Emotional Restriction, and Repressed Suffering. Higher scores indicate stronger beliefs in male dominance, rigid gender binaries, emotional suppression, and avoidance of help when in pain. In validation samples, average scores were around 58 (on a 28-140 range), suggesting generally low-to-moderate endorsement. The scale demonstrated excellent reliability (α ≈ .93) and strong validity, correlating positively with traditional masculinity norms and negatively with feminist attitudes. These outcomes help identify patterns of toxic masculinity that may impact well-being and relationships.

    Time frame: one time

07

Study locations

1 site
  • School of Health Science, Politeknik Negeri Subang
    Subang, West Java 41211, Indonesia
08

References and documents

Publications

  • Sanders SM, Garcia-Aguilera C, Borgogna NC, Sy JRT, Comoglio G, Schultz OAM, Goldman J. The Toxic Masculinity Scale: Development and Initial Validation. Behav Sci (Basel). 2024 Nov 14;14(11):1096. doi: 10.3390/bs14111096. PubMed 39594396 ↗
  • Parent MC, Gobble TD, Rochlen A. Social Media Behavior, Toxic Masculinity, and Depression. Psychol Men Masc. 2019 Jul;20(3):277-287. doi: 10.1037/men0000156. Epub 2018 Apr 23. PubMed 38250140 ↗
  • Jbilou J, Levesque N, Sonier RP, Tully PJ, Pinette-Drapeau I, Sonier V, Charbonneau A, Greenman PS, Grenier J, Chomienne MH. Canadian French Translation and Preliminary Validation of the Conformity to Masculine Norms Inventory: A Pilot Study. Am J Mens Health. 2021 Nov-Dec;15(6):15579883211057391. doi: 10.1177/15579883211057391. PubMed 34836484 ↗
  • Levant RF, McDermott R, Parent MC, Alshabani N, Mahalik JR, Hammer JH. Development and evaluation of a new short form of the Conformity to Masculine Norms Inventory (CMNI-30). J Couns Psychol. 2020 Oct;67(5):622-636. doi: 10.1037/cou0000414. Epub 2020 Feb 3. PubMed 32011153 ↗

Individual participant data

Plan to share: Undecided — Individual Participant Data (IPD) will not be shared due to confidentiality concerns and ethical restrictions outlined in the informed consent process. Participants were assured that their data would only be used for the purposes of this study and would not be shared publicly or with third parties.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07192406
Lead sponsor
Kaohsiung Medical University
Responsible party
Yudisa Diaz Lutfi Sandi (Principal Investigator, Kaohsiung Medical University) — Principal investigator
First posted
Sep 25, 2025
Start date
Sep 23, 2025
Primary completion
Nov 30, 2025
Completion
Nov 30, 2025
Last update
Jan 27, 2026

Study contacts

Novi S Nursafitri, RN
principal investigator · School of Health Science, Politeknik Negeri Subang

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion